Pdl Biopharma Inc (PDLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2006 | 09-2006 | 06-2006 | 03-2006 | 12-2005 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 179,009 | 205,133 | 205,754 | 124,203 | 183,377 |
| Marketable Securities | 154,115 | 178,992 | 198,861 | 171,862 | 101,617 |
| Receivables | 14,815 | 16,479 | 19,869 | 21,249 | 19,116 |
| Inventories | 19,663 | 22,102 | 19,728 | 20,312 | 17,728 |
| Income taxes - deferred | N/A | 4,778 | 4,778 | 4,778 | N/A |
| Other current assets | 0 | 0 | 0 | 30,000 | 30,000 |
| TOTAL | $379,496 | $438,308 | $458,046 | $398,357 | $379,354 |
| Non-Current Assets | |||||
| PPE Net | 296,529 | 269,256 | 266,798 | 267,897 | 266,053 |
| Investments And Advances | 74,892 | 34,874 | 9,728 | 49,999 | 48,928 |
| Intangibles | 355,667 | 439,438 | 433,582 | 444,148 | 455,049 |
| Other Non-Current Assets | 35,309 | 14,907 | 12,268 | 12,943 | 13,770 |
| TOTAL | $762,397 | $758,475 | $722,376 | $774,987 | $783,800 |
| Total Assets | $1,141,893 | $1,196,783 | $1,180,422 | $1,173,344 | $1,163,154 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,239 | N/A | 647 | N/A | N/A |
| Accounts payable and accrued liabilities | 13,478 | 5,406 | 7,646 | 8,803 | 2,728 |
| Accrued Expenses | 25,903 | 21,334 | 19,313 | 20,671 | 19,626 |
| Other current liabilities | N/A | 631 | N/A | 663 | 676 |
| TOTAL | $106,063 | $100,232 | $72,039 | $67,815 | $72,052 |
| Non-Current Liabilities | |||||
| Long Term Debt | 36,925 | N/A | 7,209 | 7,246 | N/A |
| Deferred Revenues | 13,443 | 8,973 | 12,040 | 12,137 | 11,290 |
| Other Non-Current Liabilities | 499,998 | 510,548 | 499,998 | 499,998 | 507,294 |
| TOTAL | $568,289 | $555,864 | $570,165 | $572,192 | $565,037 |
| Total Liabilities | $674,352 | $656,096 | $642,204 | $640,007 | $637,089 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 115,266 | 115,226 | 114,854 | 114,467 | 114,182 |
| Common Shares | 1,150 | 1,141 | 1,139 | 1,135 | 1,121 |
| Retained earnings | -570,129 | -480,421 | -473,698 | -466,339 | -440,109 |
| Other shareholders' equity | -1,326 | -598 | -1,301 | -1,802 | -4,065 |
| TOTAL | $467,541 | $540,687 | $538,218 | $533,337 | $526,065 |
| Total Liabilities And Equity | $1,141,893 | $1,196,783 | $1,180,422 | $1,173,344 | $1,163,154 |